Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 known ✓ | Q09470 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.93 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.93 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.93 |
| ▸ | TSHR | P16473 | 3/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | SHBG | P04278 | 3/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.93 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.93 |
| ▸ | FNTA | P49354 | 5/20 | 0.73 |
| ▸ | FNTB | P49356 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cortisone SCHEMBL13332835 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL13026135 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL10089738 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL9926754 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL6535496 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL4888 | 0.96 | HSD17B10 (1.00) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL8582950 | 0.95 | HSD17B10 (0.88) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082082 | 0.95 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL5082086 | 0.95 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA | |
| Cortisone SCHEMBL28542114 | 0.95 | HSD17B10 (0.98) | HSD17B10NR3C1SERPINA6TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110461315-A | Treatment and Prevention of Cytokine Release Syndrome Using Chimeric Antigen Receptors in Combination with Kinase Inhibitors | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| CN-110225927-A | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | 诺华股份有限公司 | 2019-09-10 | — | — | CN | disclosed |
| EP-1996710-B1 | RIFAXIMIN ANTI-RECTAL DYSFUNCTION PREPARATION | SALIX PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| CN-107580628-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2018-01-12 | — | — | CN | disclosed |
| CN-101594885-B | Rifaximin anti-rectal dysfunction preparation | 萨利克斯药品公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-2964196-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | Cipla Limited (IN) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | CIPLA LIMITED (MH) | 2016-01-07 | — | — | US | disclosed |
| US-20150196488-A1 | Topical Foam Composition | CIPLA LIMITED (IN) | 2015-07-16 | — | — | US | disclosed |
| US-8987292-B2 | Rifaximin anti-rectal dysfunction preparation | SALIX PHARMACEUTICALS, LTD. (US) | 2015-03-24 | — | — | US | disclosed |
| WO-2014135891-A1 | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | CIPLA LIMITED (IN) | 2014-09-12 | — | — | WO | disclosed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5693676-A | USING NITROGLYCERIN TO TREAT ANAL FISSURES OR ULCERS, HEMORRHOIDS, LEVATOR SPASMS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | disclosed |
| EP-0719145-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995032715-A1 | NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS | NEPTUNE PHARMACEUTICAL CORPORATION (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | disclosed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
| US-4432964-A | Topical composition containing steroid in two forms released independently from polymeric carrier | ALZA CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0088462-A2 | Anti-inflammatory and rheumatic composition containing organophosphonate and steroid | THE PROCTER & GAMBLE COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002278-A1 | Pharmaceutical Compositions for Rectal Administration | SI, CROCC, FABP2 | KCNA1 1970/4885HSD17B10 775/4885NR3C1 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.